JoysonKarakunnelMDMS, FACP

Oncology • Arlington, VA

Hematologic Oncology, Hospice & Palliative

Staff Hematologist-Oncologist

Join to view full profile

Dr. Karakunnel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Karakunnel's full profile

Already have an account?

Office
1635 N George Mason Dr
Suite 115
Arlington, VA 22205
Phone+1 703-243-1310

Fax+1 703-243-0128

Education & Training

University of MarylandMS, Pharmacology, 2005 - 2008
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2008
University of MarylandFellowship, Hematology and Medical Oncology, 2005 - 2006
Clinical Center at the National Institutes of HealthFellowship, Hospice and Palliative Medicine, 2005
Atlantic Health System/Overlook Medical CenterResidency, Internal Medicine, 2000 - 2003
Rajah Muthiah Medical CollegeClass of 2000

Certifications & Licensure

VA State Medical License 2005 - 2020
CA State Medical License 2017 - 2019
WI State Medical License 2012 - 2017
DC State Medical License 2015 - 2016
MD State Medical License 2003 - 2016
CT State Medical License 2012 - 2014
KY State Medical License 2013 - 2014
ME State Medical License 2012 - 2014
FL State Medical License 2008 - 2012
Join now to see all

Clinical Trials

A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer Start of enrollment: 2013 Oct 25
Completed
Phase 1
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies Start of enrollment: 2013 Dec 19
Completed
Phase 1
Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome Start of enrollment: 2014 May 20
Completed
Phase 1
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies Start of enrollment: 2014 May 19
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

144 citations
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.
Lacey J Padrón, Deena M Maurer, Mark H O'Hara, Eileen M O'Reilly, Robert A Wolff
Nature Medicine. 2022-06-01
25 citations
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translatio...
Claire F Friedman, Christine Spencer, Christopher R Cabanski, Katherine S Panageas, Daniel K Wells
Journal for Immunotherapy of Cancer. 2022-01-01
148 citations
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an ope...
Mark H. O'Hara, Eileen M. O'Reilly, Gauri R. Varadhachary, Robert A. Wolff, Zev A. Wainberg
The Lancet. Oncology. 2021-01-01

Press Mentions

Innate Pharma Presents Preliminary Data from TELLOMAK Trial Showing Clinical Response for Lacutamab in Mycosis FungoidesJune 22nd, 2021
Innate Pharma Announces Conference Call and Webcast for 2021 First Quarter Business UpdateMay 3rd, 2021
Innate Pharma Announces Conference Call and Webcast for Full Year 2020 Financial ResultsMarch 15th, 2021
Join now to see all